• Lycia Therapeutics closed its upsized IPO of 20,286,000 shares of common stock at $18 per share.
• Gross proceeds totaled approximately $365.1 million before underwriting discounts, commissions and offering expenses.
• The offering included 2,646,000 additional shares purchased through the underwriters’ full exercise of their option.
• Shares began trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol LYCA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lycia Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610261612PRIMZONEFULLFEED9853425) on October 26, 2026, and is solely responsible for the information contained therein.